Can I switch from Ozempic to Mounjaro?

Switching from Ozempic to Mounjaro is straightforward for type 2 diabetes patients. Your clinician will typically wait one week after your last Ozempic dose, then start Mounjaro at the 2.5mg starter dose, even if you were on a higher Ozempic dose. The molecules work differently — semaglutide is a GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist — so you titrate Mounjaro from the beginning regardless of Ozempic dose history. SURPASS-2 head-to-head data shows Mounjaro reduces A1C by ~2.3% vs Ozempic ~1.9%. For weight loss switching, switch to Zepbound (same tirzepatide, weight-loss FDA indication) to avoid off-label PA denials.

Can I switch from Wegovy to Zepbound?

Switching from Wegovy to Zepbound is increasingly common in 2026. Reasons include: Wegovy intolerance (severe GI side effects), weight loss plateau, or insurance coverage loss for Wegovy. Wait one week after final Wegovy dose, then start Zepbound at 2.5mg starter and titrate over 4-week intervals. SURMOUNT-1 trial showed Zepbound delivers ~22% body weight loss vs Wegovy ~15% in SELECT. The OSA-with-obesity FDA indication (December 2024) made Zepbound easier to approve on plans that previously denied weight-loss tirzepatide. LillyDirect cash-pay at $549/month is a backup if insurance denies.

Switching from Mounjaro to Zepbound (2026) — dose mapping and what to expect

Why patients switch

What drives the Mounjaro → Zepbound change

Same molecule (tirzepatide), different brand. The switch is purely administrative: Mounjaro is T2D-indicated, Zepbound is weight-loss-indicated. Patients without diabetes who were prescribed Mounjaro off-label often need to move to Zepbound for insurance compliance, or to access LillyDirect cash-pay.

Dose conversion

Mapping your dose

None. Same molecule, same cadence, same dose. Switch on next refill day.

Mounjaro dose

Zepbound dose

2.5 mg

5 mg

10 mg

15 mg

Identical

The Mounjaro-to-Zepbound switch is administrative reality, not clinical change.

LoseLab editorialMounjaro → Zepbound

What to expect

Side effect timing

No clinical difference. Identical mechanism, identical formulation. Any side effects continue as before.

Insurance

This is usually the friction. If your plan covered Mounjaro under T2D criteria and you do not have a T2D diagnosis, the prescription was off-label. Zepbound requires BMI-based PA but uses the on-label obesity pathway.

Cost shift

LillyDirect Zepbound vials are cheaper than retail Mounjaro pens. If you have no insurance or excluded coverage, switching to Zepbound saves $200-400/mo.

When to stay put

Patients who should not switch

T2D patients with successful Mounjaro coverage should not switch. Zepbound is not diabetes-indicated and your plan will not cover it.

More switching guides

Editorial summary, not medical advice. Drug switches should be coordinated with your prescriber. Dose conversions reflect typical practice; your prescriber may adjust based on tolerance, comorbidities, or interactions.

What drives the Mounjaro → Zepbound change